Loading...
•
Dec 31, 2019
scPharmaceuticals Q4 2019 Earnings Report
scPharmaceuticals reported fourth quarter and year ended 2019 financial results and provided a business update.
Key Takeaways
scPharmaceuticals reported a net loss of $10.8 million for the fourth quarter of 2019, compared to $5.1 million for the comparable period in 2018. The company ended the quarter with $72.8 million in cash, cash equivalents and restricted cash.
Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020
Initiating FUROSCIX pre-commercialization and product positioning efforts
Strong balance sheet; ending 2019 with $72.8 million in cash
Guiding 2020 quarterly GAAP expenses of $9.0 to $11.0 million
scPharmaceuticals
scPharmaceuticals
Forward Guidance
scPharmaceuticals forecasts 2020 expenditures of $9.0 to $11.0 million per quarter.